Why the study?
Does the CK-MB mass Vidas-BioMerieux immunoassay perform comparably to the Access-Sanofi-Pasteur test in patients with ischemic myocardial injury?
Population
119 blood samples from patients with ischemic myocardial injury
Comparison
CK-MB mass Vidas-BioMerieux fluorescent… vs CK-MB mass Access-Sanofi-Pasteur…
Design
Other
Authors
Loading...
Supports Vidas-BioMerieux as alternative to Access in AMI; confirms equivalence but leaves open broader validation.
Does the CK-MB mass Vidas-BioMerieux immunoassay perform comparably to the Access-Sanofi-Pasteur test in patients with ischemic myocardial injury?
The new CK-MB mass Vidas-BioMerieux fluorescent immunoassay demonstrates comparable analytical and clinical performance to the established Access-Sanofi-Pasteur test for detecting ischemic myocardial injury.
Poirey et al. (2000) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: